| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/23/2022 | 96.08% | Jefferies | $14 → $21 | Maintains | Buy |
| 08/11/2022 | 86.74% | HC Wainwright & Co. | $16 → $20 | Maintains | Buy |
| 07/13/2022 | 77.4% | RBC Capital | $14 → $19 | Maintains | Outperform |
| 02/24/2022 | 49.39% | HC Wainwright & Co. | $14 → $16 | Maintains | Buy |
| 12/13/2021 | 86.74% | Evercore ISI Group | $12 → $20 | Maintains | Outperform |
| 12/07/2021 | 2.71% | RBC Capital | $9 → $11 | Maintains | Outperform |
| 10/18/2021 | -15.97% | RBC Capital | $8 → $9 | Maintains | Outperform |
| 09/14/2021 | 30.72% | HC Wainwright & Co. | $10 → $14 | Maintains | Buy |
| 07/29/2021 | -15.97% | BTIG | → $9 | Initiates Coverage On | → Buy |
| 01/29/2021 | -25.3% | RBC Capital | → $8 | Initiates Coverage On | → Outperform |
| 11/18/2020 | 12.04% | Evercore ISI Group | → $12 | Initiates Coverage On | → Outperform |
| 08/14/2020 | -6.63% | HC Wainwright & Co. | $28 → $10 | Maintains | Buy |
| 07/07/2020 | -43.98% | Baird | $14 → $6 | Maintains | Outperform |
| 07/07/2020 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 06/26/2020 | 161.44% | HC Wainwright & Co. | → $28 | Initiates Coverage On | → Buy |
| 09/30/2019 | — | Jefferies | Initiates Coverage On | → Buy |
BELLUS Health Questions & Answers
The latest price target for BELLUS Health (NASDAQ: BLU) was reported by Jefferies on September 23, 2022. The analyst firm set a price target for $21.00 expecting BLU to rise to within 12 months (a possible 96.08% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for BELLUS Health (NASDAQ: BLU) was provided by Jefferies, and BELLUS Health maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BELLUS Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BELLUS Health was filed on September 23, 2022 so you should expect the next rating to be made available sometime around September 23, 2023.
While ratings are subjective and will change, the latest BELLUS Health (BLU) rating was a maintained with a price target of $14.00 to $21.00. The current price BELLUS Health (BLU) is trading at is $10.71, which is out of the analyst's predicted range.